Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MUC1-DC-CTL in Gastric Cancer
NCT02602249Phase 1Unknown
- Sponsor
- Beijing DOING Biomedical Technology
- Start
- Oct 2017
- Primary completion
- Apr 2019
- Modality
- Gene Editing, Whole Cell Cancer Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, randomised trial of MUC1-gene-DC-CTL and MUC1-peptide-DC-CTL in gastric cancer (GC) (3 arms), sponsored by Beijing DOING Biomedical Technology. Primary endpoint: Reduced size of the tumor at 1 year. Status: unknown.
02
Drugs
MUC1-gene-DC-CTLMUC1-peptide-DC-CTL
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT02602249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02602249.